Logo image of BLTE

BELITE BIO INC - ADR (BLTE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BLTE - US07782B1044 - ADR

129 USD
-7 (-5.15%)
Last: 11/25/2025, 10:49:06 AM
Fundamental Rating

3

BLTE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. BLTE has a great financial health rating, but its profitability evaluates not so good. BLTE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BLTE has reported negative net income.
BLTE had negative earnings in each of the past 5 years.
In the past 5 years BLTE always reported negative operating cash flow.
BLTE Yearly Net Income VS EBIT VS OCF VS FCFBLTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 0 0 0 0

1.2 Ratios

Looking at the Return On Assets, with a value of -31.21%, BLTE is in line with its industry, outperforming 51.56% of the companies in the same industry.
With a Return On Equity value of -32.45%, BLTE perfoms like the industry average, outperforming 58.85% of the companies in the same industry.
Industry RankSector Rank
ROA -31.21%
ROE -32.45%
ROIC N/A
ROA(3y)-28.65%
ROA(5y)-32.2%
ROE(3y)-30.23%
ROE(5y)-34.36%
ROIC(3y)N/A
ROIC(5y)N/A
BLTE Yearly ROA, ROE, ROICBLTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BLTE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLTE Yearly Profit, Operating, Gross MarginsBLTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for BLTE has been increased compared to 1 year ago.
There is no outstanding debt for BLTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLTE Yearly Shares OutstandingBLTE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BLTE Yearly Total Debt VS Total AssetsBLTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

There is no outstanding debt for BLTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
BLTE Yearly LT Debt VS Equity VS FCFBLTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

BLTE has a Current Ratio of 24.30. This indicates that BLTE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 24.30, BLTE belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
A Quick Ratio of 24.30 indicates that BLTE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 24.30, BLTE belongs to the top of the industry, outperforming 93.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.3
Quick Ratio 24.3
BLTE Yearly Current Assets VS Current LiabilitesBLTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BLTE have decreased strongly by -72.97% in the last year.
EPS 1Y (TTM)-72.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BLTE will show a very strong growth in Earnings Per Share. The EPS will grow by 54.92% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-65.75%
EPS Next 2Y-16.5%
EPS Next 3Y23.68%
EPS Next 5Y54.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLTE Yearly Revenue VS EstimatesBLTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
BLTE Yearly EPS VS EstimatesBLTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLTE. In the last year negative earnings were reported.
Also next year BLTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLTE Price Earnings VS Forward Price EarningsBLTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 -60 -80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLTE Per share dataBLTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

BLTE's earnings are expected to grow with 23.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.5%
EPS Next 3Y23.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELITE BIO INC - ADR

NASDAQ:BLTE (11/25/2025, 10:49:06 AM)

129

-7 (-5.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-16 2026-03-16/bmo
Inst Owners0.7%
Inst Owner Change2271.24%
Ins Owners1.31%
Ins Owner ChangeN/A
Market Cap4.50B
Revenue(TTM)N/A
Net Income(TTM)-48.68M
Analysts83.64
Price Target116.03 (-10.05%)
Short Float %1.58%
Short Ratio3.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.77%
Min EPS beat(2)-18.12%
Max EPS beat(2)-17.41%
EPS beat(4)1
Avg EPS beat(4)-8.19%
Min EPS beat(4)-18.12%
Max EPS beat(4)4.68%
EPS beat(8)3
Avg EPS beat(8)-6.29%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.98%
PT rev (3m)21.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.85%
EPS NY rev (1m)0%
EPS NY rev (3m)1.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 30.11
P/tB 30.11
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS4.28
TBVpS4.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.21%
ROE -32.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.65%
ROA(5y)-32.2%
ROE(3y)-30.23%
ROE(5y)-34.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.3
Quick Ratio 24.3
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)262.2%
Cap/Depr(5y)203.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.14%
EPS Next Y-65.75%
EPS Next 2Y-16.5%
EPS Next 3Y23.68%
EPS Next 5Y54.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-51.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.33%
OCF growth 3YN/A
OCF growth 5YN/A

BELITE BIO INC - ADR / BLTE FAQ

What is the ChartMill fundamental rating of BELITE BIO INC - ADR (BLTE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BLTE.


What is the valuation status of BELITE BIO INC - ADR (BLTE) stock?

ChartMill assigns a valuation rating of 1 / 10 to BELITE BIO INC - ADR (BLTE). This can be considered as Overvalued.


How profitable is BELITE BIO INC - ADR (BLTE) stock?

BELITE BIO INC - ADR (BLTE) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BLTE stock?

The Earnings per Share (EPS) of BELITE BIO INC - ADR (BLTE) is expected to decline by -65.75% in the next year.